SLC5A2 and myocardial infarction: A systematic review and meta-analysis by Li et al. showed that treatment with SGLT2 inhibitors reduced the risk of stroke, heart failure and hospitalization for heart failure, myocardial infarction, unstable angina and cardiovascular mortality but did not reduce the risk of atrial fibrillation [21].